Literature DB >> 17464378

Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients.

J Mark FitzGerald1, Jennifer M Haddon, Carole Bradly-Kennedy, Lisa Kuramoto, Gordon T Ford.   

Abstract

BACKGROUND: There is increasing interest in health care resource use (HRU) in Canada, particularly in resources associated with acute exacerbations of chronic obstructive pulmonary disease (COPD).
OBJECTIVE: To identify HRU due to exacerbations of COPD.
METHODS: A 52-week, multicentre, prospective, observational study of HRU due to exacerbations in patients with moderate to severe COPD was performed. Patients were recruited from primary care physicians and respirologists in urban and rural centres in Canada.
RESULTS: In total, 524 subjects (59% men) completed the study. Their mean age was 68.2+/-9.4 years, with a forced expiratory volume in 1 s of 1.01+/-0.4 L. Patients had significant comorbidities. There were 691 acute exacerbations of COPD, which occurred in 53% of patients: 119 patients (23%) experienced one acute exacerbation, 70 patients (13%) had two acute exacerbations and 89 patients (17%) had three or more acute exacerbations. Seventy-five patients were admitted to hospital, with an average length of stay of 13.2 days. Fourteen of the patients spent time in an intensive care unit (average length of stay 5.6 days). Factors associated with acute exacerbations of COPD included lower forced expiratory volume in 1 s (P<0.001), high number of respiratory medications prescribed (P=0.037), regular use of oral corticosteroids (OCSs) (P=0.008) and presence of depression (P<0.001). Of the 75 patients hospitalized, only 53 received OCSs, four received referral for rehabilitation and 15 were referred for home care.
CONCLUSIONS: The present study showed a high prevalence of COPD exacerbations, which likely impacted on HRU. There was evidence of a lack of appropriate management of exacerbations, especially with respect to use of OCSs, and referral for pulmonary rehabilitation and home care.

Entities:  

Mesh:

Year:  2007        PMID: 17464378      PMCID: PMC2676835          DOI: 10.1155/2007/921914

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  25 in total

Review 1.  Self-management education for chronic obstructive pulmonary disease.

Authors:  E M Monninkhof; P D L P M van der Valk; J van der Palen; C L A van Herwaarden; M R Partidge; E H Walters; G A Zielhuis
Journal:  Cochrane Database Syst Rev       Date:  2003

2.  Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society.

Authors:  Y Lacasse; D Brooks; R S Goldstein
Journal:  Chest       Date:  1999-08       Impact factor: 9.410

3.  Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.

Authors:  T Seemungal; R Harper-Owen; A Bhowmik; I Moric; G Sanderson; S Message; P Maccallum; T W Meade; D J Jeffries; S L Johnston; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

4.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

5.  Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.

Authors:  Jean Bourbeau; Marcel Julien; François Maltais; Michel Rouleau; Alain Beaupré; Raymond Bégin; Paolo Renzi; Diane Nault; Elizabeth Borycki; Kevin Schwartzman; Ravinder Singh; Jean-Paul Collet
Journal:  Arch Intern Med       Date:  2003-03-10

6.  Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD.

Authors:  Marc Miravitlles; Cristina Murio; Tina Guerrero; Ramon Gisbert
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

7.  Risk of depression in patients with chronic obstructive pulmonary disease and its determinants.

Authors:  J G van Manen; P J E Bindels; F W Dekker; C J IJzermans; J S van der Zee; E Schadé
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

8.  The influence of co-morbidity on health-related quality of life in asthma and COPD patients.

Authors:  H A H Wijnhoven; D M W Kriegsman; A E Hesselink; M de Haan; F G Schellevis
Journal:  Respir Med       Date:  2003-05       Impact factor: 3.415

Review 9.  Pulmonary rehabilitation for chronic obstructive pulmonary disease.

Authors:  Y Lacasse; L Brosseau; S Milne; S Martin; E Wong; G H Guyatt; R S Goldstein
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.

Authors:  Shawn D Aaron; Katherine L Vandemheen; Paul Hebert; Robert Dales; Ian G Stiell; Jan Ahuja; Garth Dickinson; Robert Brison; Brian H Rowe; Jonathan Dreyer; Elizabeth Yetisir; Daniel Cass; George Wells
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

View more
  25 in total

1.  Health literacy, language, and ethnicity-related factors in newcomer asthma patients to Canada: a qualitative study.

Authors:  Iraj Poureslami; Irving Rootman; Mary M Doyle-Waters; Laura Nimmon; J Mark Fitzgerald
Journal:  J Immigr Minor Health       Date:  2011-04

Review 2.  Burden of chronic obstructive pulmonary disease: healthcare costs and beyond.

Authors:  Sara M May; James T C Li
Journal:  Allergy Asthma Proc       Date:  2015 Jan-Feb       Impact factor: 2.587

3.  Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD).

Authors:  Emily S Wan; Dawn L DeMeo; Craig P Hersh; Steven D Shapiro; Richard A Rosiello; Susan R Sama; Anne L Fuhlbrigge; Marilyn G Foreman; Edwin K Silverman
Journal:  Respir Med       Date:  2010-12-10       Impact factor: 3.415

4.  Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy.

Authors:  O Zaniolo; S Iannazzo; L Pradelli; M Miravitlles
Journal:  Eur J Health Econ       Date:  2010-11-18

5.  A new method for examining the cost savings of reducing COPD exacerbations.

Authors:  Douglas W Mapel; Michael Schum; Eva Lydick; Jeno P Marton
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Effects of depression diagnosis and antidepressant treatment on mortality in Medicare beneficiaries with chronic obstructive pulmonary disease.

Authors:  Jingjing Qian; Linda Simoni-Wastila; Patricia Langenberg; Gail B Rattinger; Ilene H Zuckerman; Susan Lehmann; Michael Terrin
Journal:  J Am Geriatr Soc       Date:  2013-04-25       Impact factor: 5.562

7.  Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD.

Authors:  Joseph Seaman; Anthony C Leonard; Ralph J Panos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-04-07

8.  A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease.

Authors:  Charles K N Chan; François Maltais; Chris Sigouin; Jennifer M Haddon; Gordon T Ford
Journal:  Can Respir J       Date:  2007 Nov-Dec       Impact factor: 2.409

9.  Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure.

Authors:  Sabrina Storgaard Sørensen; Line Hust Storgaard; Ulla Møller Weinreich
Journal:  Clinicoecon Outcomes Res       Date:  2021-06-18

10.  The feasibility and validity of a remote pulse oximetry system for pulmonary rehabilitation: a pilot study.

Authors:  Jonathan Tang; Allison Mandrusiak; Trevor Russell
Journal:  Int J Telemed Appl       Date:  2012-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.